← Oncology Approval Tracker

FDA DECISION ·

Osvyrti

denosumab-desu · Accord BioPharma

Biosimilar approvalBiosimilarBone loss during cancer hormone therapy
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Prolia biosimilar with oncology uses for increasing bone mass in men at high fracture risk on androgen deprivation for nonmetastatic prostate cancer and women at high fracture risk on adjuvant aromatase inhibitors for breast cancer.

LAMPGEN ANALYSIS

Why it matters

This denosumab presentation adds a biosimilar option for bone loss associated with specific breast and prostate cancer hormone treatments.

What research teams should watch

Train staff to verify the intended reference and measure renal and mineral risk according to the relevant label.

PRIMARY RECORDS

Sources